Trunk and Extremity Melanoma Debate: Similar Outcomes for Mohs Micrographic Surgery Versus Wide Local Excision

Survival outcomes did not change significantly for patients with melanoma of the trunk or extremity when treated with Mohs micrographic surgery (MMS) compared with wide local excision, according to the results of a retrospective cohort study published recently in JAMA Dermatology. The retrospective cohort study was designed because previous studies indicated differences in overall survival outcomes for patients with head and neck cancers. However, this study indicates that those results do not a...
Continue reading

Venous Thromboembolism Recurrence in Patients With Cancer

In patients with cancer who develop venous thromboembolism (VTE), cancer type plays a significant role in the risk of VTE recurrence after anticoagulation. A condition involving the formation of a blood clot that starts in a vein, VTE can negatively impact the clinical outcomes of patients undergoing cancer treatment. While anticoagulation therapies, including apixaban and rivaroxaban, are mainstays of treatment, patients with cancer experience higher rates of anticoagulation failure and bleedin...
Continue reading

Nadofaragene for High-Grade BCG-Unresponsive NMIBC

​Intravesical nadofaragene firadenovec is an effective and well-tolerated treatment for high-grade nonmuscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) that does not respond to intravesical Bacillus Calmette-Guerin (BCG), according to results of a multicenter, open-label phase 3 trial presented this past Friday at the 2020 Genitourinary Cancers Symposium. For patients with BCG-unresponsive NMIBC, there is a substantial risk of disease recurrence and progression. Cystectomy is often ...
Continue reading

Continued Induction, Maintenance, or Observation: Which Is Most Effective for Metastatic Colorectal Cancer?

For patients with metastatic colorectal cancer, the standard treatment is induction combination chemotherapy with a targeted agent. However, clinical trials that involved patients either continuing cytotoxic therapy until disease progression or observation have shown inconsistent efficacy results. To close this gap, a systematic review and network meta-analysis was conducted and revealed that continued induction therapy until progression offered no survival benefit compared with maintenance fluo...
Continue reading

What Are the Most Common Causes of Death for Breast Cancer Survivors?

Researchers discovered that a significant number of breast cancer survivors die from heart and cerebrovascular diseases, providing important insight on how breast cancer survivors should be counseled on potential health risks. In this study, published in Cancer, data on 754,270 women who were diagnosed with breast cancer during 2000 through 2015 from the Surveillance, Epidemiology, and End Results (SEER) program were analyzed. The researchers then calculated standardized mortality ratios for cau...
Continue reading

Microvascular Endothelial Dysfunction Predicts Solid Tumor Cancer Risk

Microvascular endothelial dysfunction (MED), which is characterized by damage to the walls of small arteries in the heart, limiting the regulation of oxygen and blood supply, serves as an effective predictor of cardiovascular disease. In addition, a recent study reports, MED significantly increases an individual's risk of developing solid-tumor cancer. In a study now published in the European Journal of Preventive Cardiology, Amir Lerman, MD, the Director of Cardiovascular Research at Mayo Clini...
Continue reading

High Dairy Consumption Increases Prostate Cancer Risk

Among cancers that affect men, prostate cancer is the most common and carries the second highest rate of mortality. How does diet play a role in this widespread public health concern, which affects 11.6% of American men at some time in their lives? A new literature review published in The Journal of the American Osteopathic Association reports that consuming high amounts of dairy may increase prostate cancer risk, while consuming high amounts of plant-based foods may decrease risk. "Previous stu...
Continue reading

Fedratinib Approved for Myelofibrosis

​The FDA has now approved fedratinib (Inrebic®, Impact Biomedicines, Inc./Celgene Corporation) for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis. A myeloproliferative neoplasm, myelofibrosis can either present as a primary condition or as a secondary condition following the transformation of polycythemia vera or essential thrombocythemia. Myelofibrosis causes anemia, splenomegaly, and debilitating symptoms, and it shortens survival. "Prior to today, there was on...
Continue reading

​Safe Dose of Regorafenib For Metastatic Colorectal Cancer

In patients with refractory metastatic colorectal cancer, regorafenib (Stivarga®, Bayer) provides a good overall survival benefit. Unfortunately, it also causes a lot of side effects, such as infection, severe bleeding, tears in the stomach or intestinal wall, hand-foot skin reaction, severe skin rash, high blood pressure, decreased blood flow to the heart, heart attack, reversible posterior leukoencephalopathy syndrome, and wound healing problems, all of which limit its usefulness. In order to ...
Continue reading

The Need to Expand Lung Cancer Screening Criteria

Since lung cancer is the leading cause of cancer-related death worldwide because most patients are diagnosed when they already have advanced disease, effective screening is of the utmost importance. The United States Preventative Services Task Force (USPSTF) recommends screening for all individuals aged 55 to 80 with a smoking history of 30 or more pack years—a pack year being the number of packs smoked per day multiplied by the number of years a person has smoked—who either currently smoke or h...
Continue reading

Telerehabilitation Helps Patients With Advanced Cancer

​According to a new study, telerehabilitation can help patients with advanced cancer by improving function and decreasing pain, length of hospital stay, and requirements for postacute care. Patients with advanced cancer can experience disabling losses of function that impact their quality of life and increase their use of health care services. In addition, impaired mobility can increase the frequency and length of hospital stays. Rehabilitation services and conditioning activities can help to re...
Continue reading

Follicular Lymphoma: Types of T Cells Affect Outcome

Researchers have identified subtypes of T cells occurring within the follicular lymphoma (FL) microenvironment that have differing impacts on patients' chances of survival. With a median five-year survival of 74% for patients with FL treated with chemoimmunotherapy, this form of treatment has substantially improved outcomes. For a subset of patients who experience early disease progression, however, survival rates remain very low. Part of the reason for the poor outcome among these patients is a...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.